Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Subscribe To Our Newsletter & Stay Updated